Daily Bulletin

The Conversation

  • Written by Nial Wheate, Senior Lecturer in Pharmaceutics, University of Sydney

This week, the government announced the latest additions, amendments, and deletions from the Pharmaceutical Benefits Scheme (PBS): the program through which essential medicines are subsidised for Australian patients. The new medicines on the scheme are reportedly worth A$310 million.

Listing on the PBS is different to a drug being approved for sale by Australia’s drug regulator, the Therapeutic Goods Administration (TGA). Once approved by the TGA, it is available to patients and hospitals at the full price. It only becomes subsidised if later listed on the PBS.

Some of the notable additions to the list include drugs to treat eye infections, human immunodeficiency virus (HIV), cystic fibrosis, multiple sclerosis, cancer, and idiopathic pulmonary fibrosis – a type of scarring in the lungs. Below is a list of seven most notable new additions to the scheme.

1. Chloramphenicol eye drops (Chlorsig)

Chloramphenicol is the generic name of an antibiotic drug used to treat eye infections. It has been added to the PBS with the restriction that it is only available to patients who identify as Aboriginal or Torres Strait Islander (ATSI).

The rate of eye infections, like trachoma (which leads to blindness), is three times higher for ATSI patients than for other Australians. The lower price for ATSI patients is because of extra funding under the government’s Closing the Gap PBS co-payment program.

2. Ivacaftor (Kalydeco)

  • Maximum price from the manufacturer: A$22,547.02

  • Maximum cost to the patient: A$38.80

Ivacaftor – first approved by the TGA in September 2016 – is used to treat cystic fibrosis, a genetic disorder that affects the digestive system and lungs of patients. It causes a buildup of thick and sticky mucus in the airways.

There is no cure for cystis fibrosis, but ivacaftor acts by better regulating the flow of salts and water in and out of cells, which leads to less mucus buildup.

While around 3,300 people in Australia live with cystic fibrosis, only around 10% of patients will benefit from the drug. This is because patients need to have a specific mutation in their DNA called R117H for the drug to be effective.

More information - Weekly Dose: Kalydeco, the drug that treats the cause of cystic fibrosis, not just symptoms

3. Blinatumomab (Blincyto)

  • Maximum price from the manufacturer: A$61,975.54

  • Maximum cost to the patient: A$38.80

Blinatumomab is a new type of immunotherapy – a treatment that empowers the body’s immune system to fight diseases such as cancer.

The drug is approved for use to treat a specific subset of acute lymphoblastic leukaemias (ALL). Around 350 Australians each year are diagnosed with some form of ALL, and it is the most common type of cancer in children.

Blinatumomab was first approved by the TGA in November 2015 but an application to list the medicine on the PBS that same year was rejected. It has been reported that the cost for patients before the PBS subsidy was A$127,700 per course of treatment.

4. Fosaprepitant (Emend IV)

This drug is used to help patients overcome the nausea and vomiting side-effects associated with chemotherapy treatment. Fosaprepitant has been available for doctors to prescribe since 2011, when it was first recommended to be put on the PBS.

5. Emtricitabine

  • Maximum price from the manufacturer: A$1,500 - $2,600 depending on the formulation

  • Maximum cost to the patient: A$38.80

Four formulations of this drug have been added to the PBS as part of a cocktail of medicines used to treat HIV infection.

Emtricitabine acts by stopping the HIV virus from copying itself into human cells. It was first approved by the TGA in 2005 and other formulations of the drug – such as it being coupled with antiviral Tenofovir under the brand name Truvada – have been listed on the PBS previously. In Australia, there are around 25,000 people living with HIV.

More information: Weekly Dose: Truvada, the drug that can prevent HIV infection

6. Daclizumab (Zinbryta)

  • Maximum price from the manufacturer: A$2,231

  • Maximum cost to the patient: A$38.80

Daclizumab is used to treat multiple sclerosis (MS), a condition that affects the nervous system and interferes with nerve impulses in the brain, spinal chord, and optic nerves (those responsible for vision). It was first approved by the TGA in September 2016.

While there is no cure for MS, this drug helps to stop infection-fighting blood cells called T-cells from getting into the brain. This protects the brain from swelling. There are currently around 24,000 Australians who live with MS.

7. Nintedanib (Ofev)

  • Maximum price from the manufacturer: A$3,385.48

  • Maximum cost to the patient: A$38.80

Nintedanib was approved by the TGA in September 2015. It is used to treat idiopathic pulmonary fibrosis, a condition that causes scarring in the lungs. The amount of scar disease builds up over time. While nintedanib does not cure patients, it provides relief by stopping the enzymes that help create the scarring, thus slowing the disease.

The condition is most prevalent in people over 60 years of age, and affects around 2,600 Australians.

Authors: Nial Wheate, Senior Lecturer in Pharmaceutics, University of Sydney

Read more http://theconversation.com/new-drugs-on-the-pbs-what-they-do-and-why-we-need-them-77090

Writers Wanted

Physical Therapist Talks About This New Massage Gun On The Block - The HYDRAGUN


Too much information: the COVID work revolution has increased digital overload


Ammonite: the remarkable real science of Mary Anning and her fossils


The Conversation


Prime Minister's Remarks to Joint Party Room

PRIME MINISTER: Well, it is great to be back in the party room, the joint party room. It’s great to have everybody back here. It’s great to officially welcome Garth who joins us. Welcome, Garth...

Scott Morrison - avatar Scott Morrison

Prime Minister Interview with Ben Fordham, 2GB

BEN FORDHAM: Scott Morrison, good morning to you.    PRIME MINISTER: Good morning, Ben. How are you?    FORDHAM: Good. How many days have you got to go?   PRIME MINISTER: I've got another we...

Scott Morrison - avatar Scott Morrison

Prime Minister Interview with Kieran Gilbert, Sky News

KIERAN GILBERT: Kieran Gilbert here with you and the Prime Minister joins me. Prime Minister, thanks so much for your time.  PRIME MINISTER: G'day Kieran.  GILBERT: An assumption a vaccine is ...

Daily Bulletin - avatar Daily Bulletin

Business News

Getting Ready to Code? These Popular and Easy Programming Languages Can Get You Started

According to HOLP (History Encyclopedia of Programing Languages), there are more than 8,000 programming languages, some dating as far back as the 18th century. Although there might be as many pr...

News Co - avatar News Co

Avoid These Mistakes When Changing up Your Executive Career

Switching up industries is a valid move at any stage in your career, even if you’re an executive. Doing so at this stage can be a lot more intimidating, however, and it can be quite difficult know...

News Co - avatar News Co

4 Costly Mistake To Avoid When Subdividing Your Property

As a property developer or landowner, the first step in developing your land is subdividing it. You subdivide the property into several lots that you either rent, sell or award to shareholders. ...

News Co - avatar News Co

News Co Media Group

Content & Technology Connecting Global Audiences

More Information - Less Opinion